Search Bar & Filters
Found 19 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating TQB2102, an antibody-drug conjugate designed to target Human Epidermal Growth Factor Receptor 2 HER2 positive tumor cells, in patients with recurrent or metastatic advanced gynecological tumors. This Phase 2 study aims to assess the safety and effectiveness of TQB2102 in this patient population, addressing the need for new treatments after unsuccessful platinum-based chemotherapy. Participants will receive TQB2102 through intravenous infusion every three weeks, with each treatment cycle lasting 21 days. This investigational drug combines a humanized antibody with a potent drug payload to specifically attack tumor cells. The study includes monitoring for adverse events and anti-drug antibodies during treatment and follow-up. During the trial, participants will undergo regular assessments including tumor measurements to evaluate overall response rate, duration of remission, progression-free survival, overall survival, and disease control rate for up to 12 to 17 months. Safety evaluations will continue until 28 days after the last dose or the start of new cancer therapies. Blood samples for anti-drug antibody testing will be collected at specific treatment cycles and after treatment completion. The total involvement period depends on individual treatment duration and follow-up schedules.
Actively Recruiting
Researchers are evaluating the safety and effects of a medicine called Fosmanogepix for treating candidemia and invasive candidiasis, serious fungal infections caused by Candida species. This Phase 3 study compares Fosmanogepix with standard treatments to see if it works at least as well as current therapies. The trial involves adult patients diagnosed with these infections, aiming to assess treatment success and patient survival. Participants receive one of two treatments two-thirds get Fosmanogepix through an intravenous IV infusion daily at the clinic, with an option to switch to oral tablets if well enough to continue treatment at home. One-third receive the standard care of Caspofungin IV infusion followed by oral Fluconazole capsules. Matching placebos are used for blinding. Treatment can last up to 6 weeks depending on infection clearance and symptom improvement. During the study, participants undergo regular assessments including blood tests and monitoring for treatment success and safety. Researchers measure survival at 30 days and response rates at multiple time points, including after treatment ends and at a 6-week follow-up. The study tracks adverse events, lab abnormalities, and drug levels to evaluate safety and treatment effects. Total participation can last up to about 12.5 weeks with follow-up visits to monitor long-term outcomes.
Actively Recruiting
Healthy Volunteer
Chronic kidney disease CKD involves damage to the kidneys structure or function and affects a significant portion of the population in China, with a prevalence of 10.8%. CKD not only leads to severe kidney failure requiring treatments like dialysis but also raises the risk of cardiovascular diseases, placing a heavy burden on individuals and the healthcare system. This research aims to improve understanding of CKD occurrence, progression, treatment, prognosis, and risk factors in the Chinese population through a large-scale, real-world observational study. The study is a multi-center, prospective observational registry involving participants from various centers across mainland China. It collects and integrates standardized data to efficiently analyze CKD patterns and outcomes. The study includes both CKD patients and individuals with risk factors such as hypertension, diabetes, or hyperlipidemia, as well as healthy participants, to allow broad representation and subgroup analysis. The study is designed to cover a large sample size and account for potential loss to follow-up. Participants will be observed over up to 5 years to monitor the development of CKD in non-CKD individuals and the progression of disease in those with CKD. Researchers will track changes in kidney function, albuminuria levels, and composite endpoints including disease progression and mortality. Data collection includes clinical assessments and laboratory measurements to evaluate disease markers and outcomes. The study offers long-term monitoring to better understand CKD dynamics and inform prevention and control strategies.
Actively Recruiting
Researchers are evaluating the effect of a triple therapy inhaler containing budesonide, glycopyrronium, and formoterol fumarate BGF MDI 32014.49.6 g compared to a dual therapy inhaler with glycopyrronium and formoterol fumarate GFF MDI 14.49.6 g on heart and lung outcomes in adults with chronic obstructive pulmonary disease COPD who have increased cardiopulmonary risk. This is a Phase III randomized, double-blind, parallel group, multi-center study designed to assess these treatments over an extended period. Participants will be randomly assigned to receive either the triple therapy BGF MDI or the dual therapy GFF MDI, each administered twice daily. The study aims to track the time to first severe cardiac or COPD event over up to three years. Both treatments involve pressurized inhalation suspensions delivered by metered-dose inhalers, and the study includes ongoing monitoring for up to three years during which various cardiopulmonary events and exacerbations will be recorded. During the study, participants will attend visits where their inhaler technique, lung function, blood markers such as eosinophil counts, and COPD assessment test scores will be evaluated. Researchers will measure outcomes including time to severe COPD exacerbations, cardiac events, cardiopulmonary death, and hospitalizations related to heart issues. Safety and efficacy will be closely monitored throughout the study duration, which may last up to three years, with regular follow-up assessments conducted in person or virtually as needed.
Actively Recruiting
Healthy Volunteer
Researchers are evaluating BBT002, a drug being studied to assess its safety, tolerability, pharmacokinetics, immunogenicity, pharmacodynamics, and clinical activity in both healthy volunteers and people with Chronic Obstructive Pulmonary Disease COPD. The study is a randomized, double-blind, placebo-controlled trial conducted in two parts, including single and multiple ascending dose evaluations. This research aims to understand how BBT002 behaves in the body and its effects over time in these groups. The trial has two parts Part A involves administering a single dose of BBT002 or placebo to healthy volunteers in sequential dose groups. Part B involves giving two repeated doses of BBT002 or placebo to participants with COPD. Each participant will receive either the study drug or placebo depending on their group assignment. The study monitors responses to both single and multiple doses, with treatments given under close medical supervision. Participants will undergo assessments including monitoring for adverse events, laboratory tests, vital sign checks, physical exams, and electrocardiograms ECGs up to 141 days after dosing in healthy volunteers and up to 169 days in COPD patients. Pharmacokinetic measurements such as drug concentration and clearance will be collected at specified times. The study also tracks immune responses to the drug. Overall participation involves multiple visits and evaluations over several months to ensure comprehensive safety and activity data.
Actively Recruiting
Researchers are evaluating the safety and activity of vedolizumab intravenous infusion as a treatment for adults in China with moderately to severely active Crohns Disease. This phase 3 study involves about 408 participants and compares vedolizumab with a placebo during a 14-week induction period. The study aims to assess clinical response and remission, as well as endoscopic response, to understand how vedolizumab works for this condition. Participants will receive vedolizumab 300 mg intravenous infusions at Weeks 0, 2, and 6 during the induction period, or placebo infusions on the same schedule. After Week 14, all participants continue in an open-label extension period receiving vedolizumab every 8 weeks. From Week 18 onward, those who do not respond well or whose disease worsens may receive vedolizumab every 4 weeks. This treatment phase lasts about 58 weeks. During the study, participants will attend up to 20 visits for assessments including clinical evaluations, endoscopic exams, and safety monitoring. Researchers will track clinical response, remission, adverse events, laboratory results, and vital signs through Week 14 and up to 18 weeks after the last dose. A final safety follow-up occurs 18 weeks after the last dose, and a long-term safety survey is conducted six months later via telephone. Overall, participants will be involved in the study for approximately 58 weeks plus follow-up periods.
Actively Recruiting
Researchers are evaluating the effectiveness and safety of a new drug called GSK3862995B in adults with bronchiectasis, a chronic lung disease. This Phase 2 study also examines how the body processes the drug and checks for any immune reactions. Participants will be randomly assigned to receive one of two doses of GSK3862995B or a placebo to compare their effects on bronchiectasis. Participants will receive either Dose Level 1 or Dose Level 2 of GSK3862995B, or a matching placebo. The study uses a double-blind, randomized design, meaning neither participants nor researchers know who gets which treatment. The treatment period lasts up to 48 weeks, during which participants receive repeated doses. The study also includes assessments up to 72 weeks to monitor safety and immune responses. During the trial, participants will undergo evaluations including lung function tests, quality-of-life questionnaires, and monitoring of respiratory symptoms. Researchers will track the number of lung exacerbations, serious adverse events, laboratory tests, vital signs, and electrocardiograms to assess safety and effectiveness. Participants will be involved in regular visits and assessments throughout the treatment and follow-up periods, lasting up to about 72 weeks in total.
Actively Recruiting
Researchers are evaluating 9MW1911 in adults aged 40 to 75 who have been diagnosed with Chronic Obstructive Pulmonary Disease COPD for at least one year. This Phase II clinical trial is designed to assess how well 9MW1911 works and how safe it is for treating COPD. The study compares two different doses of 9MW1911 given intravenously with a placebo, and aims to better understand treatment effects on COPD flare-ups and lung function. Participants receive intravenous infusions of either 9MW1911 in one of two dose levels or a placebo every 28 days. Each treatment group includes 120 patients, all receiving stable standard care for COPD. The study lasts for 52 weeks of treatment, followed by safety and immune response monitoring up to 60 weeks. Researchers measure lung function, COPD exacerbations, quality of life, and other health markers during this period. During the study, participants will have regular visits for lung function tests, questionnaires about COPD symptoms and quality of life, blood tests, and safety assessments. These assessments occur at multiple time points, such as weeks 0, 4, 8, 12, 24, 36, and 52. The main outcome is the rate of moderate to severe COPD exacerbations over one year. Additional measures include lung function changes, time to first exacerbation, and biological markers. Safety and tolerability are followed for up to 60 weeks to ensure participant well-being throughout the trial.
Actively Recruiting
Evaluation of AHB-137 Injection Compared to Placebo in Adults Aged 18 to 65 With Chronic Hepatitis B
Researchers are evaluating the effectiveness and safety of AHB-137 injection in adults aged 18 to 65 with chronic hepatitis B who have not previously received treatment. This randomized, double-blind, placebo-controlled, multicenter phase 2 study aims to compare AHB-137 with a placebo to better understand its impact on the disease. Participants will receive either AHB-137 or a placebo through subcutaneous injections. The study involves monitoring viral markers such as HBV DNA and HBsAg levels during and after treatment. The treatment period and follow-up last up to 48 weeks, during which multiple virological, serological, and safety assessments will be conducted. Throughout the study, participants will undergo regular evaluations including laboratory tests for viral load and liver function, measurement of quality of life, and monitoring for adverse events. The researchers will track the proportion of participants achieving certain virological milestones and seroconversion rates. Safety assessments and drug concentration measurements will also be performed. The total participation duration extends through treatment and post-treatment observation up to 48 weeks.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of tezepelumab, a biological drug, in adults aged 40 to 80 with moderate to very severe chronic obstructive pulmonary disease COPD. This Phase 3, randomized, double-blind, placebo-controlled study includes participants who have experienced worsening COPD symptoms despite inhaled maintenance therapy. The study aims to reduce the rate of moderate or severe COPD exacerbations, which are episodes when symptoms worsen significantly. Participants will receive monthly subcutaneous injections of either one of two doses of tezepelumab or a matching placebo for a minimum of 52 weeks and up to 76 weeks. After the treatment period, there is a 12-week safety follow-up without treatment. The study compares tezepelumabs effects to placebo to evaluate its impact on lung function, COPD symptoms, and exacerbation frequency. Throughout the study, participants will undergo regular assessments including lung function tests, symptom questionnaires, and blood tests to monitor immune response and drug levels. Researchers will track COPD exacerbations and quality of life changes using tools like the St. Georges Respiratory Questionnaire and COPD Assessment Test. Safety will be monitored during and after treatment, with the entire participation lasting up to about 88 weeks including follow-up.
1-10 of 19
1